VTRS Stock Analysis: Viatris | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 19.029m USD | 12M Return: 86.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 161M
EPS Trend: -96.1%
Qual. Beats: 4
Rev. Trend: -90.3%
Qual. Beats: 4
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Viatris Inc. is a global healthcare company headquartered in Canonsburg, Pennsylvania, operating across North America, Europe, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets through four reporting segments. It markets a broad portfolio spanning prescription brand drugs, generic drugs, complex generics, and biosimilars across therapeutic areas including cardiovascular, oncology, immunology, dermatology, respiratory, and infectious diseases.
Products are delivered in oral solid, injectable, and complex dosage forms and distributed through wholesalers, retailers, mail-order and e-commerce pharmacies, and specialty channels serving governments, payers, and institutions. Viatris holds a portfolio of established brands-including Lyrica, Lipitor, Viagra, EpiPen Auto-Injector, Celebrex, Creon, and Xanax-and supplements internal development with collaboration agreements, such as those with Mapi Pharma, Revance Therapeutics, and Theravance Biopharma.
The pharmaceuticals sub-industry in which Viatris operates is characterized by heavy regulatory oversight, long product life cycles, and the typical trade-off between higher-margin branded and specialty products and the volume-driven, lower-margin generics and biosimilars business. Its combination of branded and generic exposure across both mature and emerging markets is a common model used by diversified pharma companies to stabilize revenue through patent expirations and geographic diversification.
- Generic pricing erosion pressures Developed Markets revenue and margins
- Branded portfolio declines post Lyrica and Lipitor exclusivity loss
- Deleveraging progress boosts free cash flow and capital returns
| Net Income: -296.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.17 > 1.0 |
| NWC/Revenue: 28.20% < 20% (prev 27.23%; Δ 0.97% < -1%) |
| CFO/TA 0.06 > 3% & CFO 2.17b > Net Income -296.5m |
| Net Debt (12.8b) to EBITDA (2.57b): 4.99 < 3 |
| Current Ratio: 1.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.18b) vs 12m ago -1.43% < -2% |
| Gross Margin: 34.40% > 18% (prev 36.85%; Δ -2.45% > 0.5%) |
| Asset Turnover: 38.67% > 50% (prev 37.25%; Δ 1.43% > 0%) |
| Interest Coverage Ratio: -0.51 > 6 (EBIT TTM -244.4m / Interest Expense TTM 475.9m) |
| A: 0.11 (Total Current Assets 10.9b - Total Current Liabilities 6.81b) / Total Assets 36.8b |
| B: -0.01 (Retained Earnings -211.9m / Total Assets 36.8b) |
| C: -0.01 (EBIT TTM -244.4m / Avg Total Assets 37.7b) |
| D: 0.66 (Book Value of Equity 14.7b / Total Liabilities 22.2b) |
| Altman-Z'' = 1.36 = BB |
| DSRI: 0.89 (Receivables 3.08b/3.39b, Revenue 14.6b/14.3b) |
| GMI: 1.07 (GM 36.85% / 34.40%) |
| AQI: 0.94 (AQ_t 0.63 / AQ_t-1 0.67) |
| SGI: 1.02 (Revenue 14.6b / 14.3b) |
| TATA: -0.07 (NI -296.5m - CFO 2.17b) / TA 36.8b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at USD 16.39 with a total of 5,786,253 shares traded. Over the past week, the price has changed by -2.44%, over one month by +0.43%, over three months by +19.38% and over the past year by +86.39%.
Current recommended Stop Loss: 15.40 (which is 6% or 2.1 ATR below the current price).
Viatris has received a consensus analysts rating of 3.44. Therefore, it is recommended to hold VTRS.
- StrongBuy: 2
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 17.8 | 8.7% |
P/E Forward = 6.7568
P/S = 1.3067
P/B = 1.3236
P/EG = 0.1436
Revenue TTM = 14.6b USD
EBIT TTM = -244.4m USD
EBITDA TTM = 2.57b USD
Long Term Debt = 12.4b USD (from longTermDebt, last quarter)
Short Term Debt = 1.93b USD (from shortTermDebt, last quarter)
Debt = 14.6b USD (from shortLongTermDebtTotal, last quarter) + Leases 268.9m
Net Debt = 12.8b USD (calculated: Debt 14.6b - CCE 1.80b)
Enterprise Value = 31.8b USD (19.0b + Debt 14.6b - CCE 1.80b)
Interest Coverage Ratio = -0.51 (Ebit TTM -244.4m / Interest Expense TTM 475.9m)
EV/FCF = 18.62x (Enterprise Value 31.8b / FCF TTM 1.71b)
FCF Yield = 5.37% (FCF TTM 1.71b / Enterprise Value 31.8b)
FCF Margin = 11.74% (FCF TTM 1.71b / Revenue TTM 14.6b)
Net Margin = -2.04% (Net Income TTM -296.5m / Revenue TTM 14.6b)
Gross Margin = 34.40% ((Revenue TTM 14.6b - Cost of Revenue TTM 9.55b) / Revenue TTM)
Gross Margin QoQ = 32.90% (prev 30.63%)
Tobins Q-Ratio = 0.86 (Enterprise Value 31.8b / Total Assets 36.8b)
Interest Expense / Debt = 3.26% (Interest Expense 475.9m / Debt 14.6b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -193.1m (EBIT -244.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.60 (Total Current Assets 10.9b / Total Current Liabilities 6.81b)
Debt / Equity = 1.00 (Debt 14.6b / totalStockholderEquity, last quarter 14.7b)
Debt / EBITDA = 4.99 (Net Debt 12.8b / EBITDA 2.57b)
Debt / FCF = 7.49 (Net Debt 12.8b / FCF TTM 1.71b)
Total Stockholder Equity = 15.0b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.79% (Net Income -296.5m / Total Assets 36.8b)
RoE = -1.97% (Net Income TTM -296.5m / Total Stockholder Equity 15.0b)
RoCE = -0.89% (EBIT -244.4m / Capital Employed (Equity 15.0b + L.T.Debt 12.4b))
RoIC = -0.62% (negative operating profit) (NOPAT -193.1m / Invested Capital 31.2b)
WACC = 6.08% (E(19.0b)/V(33.6b) * Re(8.78%) + D(14.6b)/V(33.6b) * Rd(3.26%) * (1-Tc(0.21)))
Discount Rate = 8.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.44 | Cagr: -0.92%
[DCF] Terminal Value 74.35% ; FCFF base≈1.77b ; Y1≈1.66b ; Y5≈1.54b
[DCF] Fair Price = 9.90 (EV 24.3b - Net Debt 12.8b = Equity 11.5b / Shares 1.16b; r=8.35% [WACC [floored]]; 5y FCF grow -7.57% → 2.50% )
EPS Correlation: -96.10 | EPS CAGR: -9.72% | SUE: 2.54 | # QB: 4
Revenue Correlation: -90.27 | Revenue CAGR: -3.72% | SUE: 1.75 | # QB: 4
EPS current Quarter (2026-06-30): EPS=0.60 | Chg30d=-0.93% | Revisions=+0% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.65 | Chg30d=-0.40% | Revisions=-70% | Analysts=8
EPS current Year (2026-12-31): EPS=2.46 | Chg30d=+0.28% | Revisions=+18% | GrowthEPS=+4.9% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=2.66 | Chg30d=-0.46% | Revisions=-18% | GrowthEPS=+8.1% | GrowthRev=+1.8%
[Analyst] Revisions Ratio: -22% (up=11, down=18)